Maria Eberg
Overview
Explore the profile of Maria Eberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wharton S, Belloum A, Luckevich M, Kamran E, Luguzis A, Eberg M, et al.
Clin Obes
. 2024 Nov;
15(2):e12720.
PMID: 39582393
This study aimed to describe the characteristics, healthcare resources utilized and costs incurred by adults receiving publicly funded obesity care in Ontario, Canada. People living with obesity who first visited...
2.
Bessissow T, Narula N, Ma C, In T, Pone E, Eberg M, et al.
Dig Liver Dis
. 2024 May;
56(10):1690-1697.
PMID: 38821813
Background/aims: Real-world healthcare resource utilization (HCRU) of bio-naïve patients with Crohn's disease (CD) receiving ustekinumab was assessed. Methods: A multicentre, retrospective chart review study of bio-naïve Canadian adult patients with...
3.
Cheung W, Samimi S, Ma K, Knight G, Kassam S, Colwell B, et al.
Clin Colorectal Cancer
. 2023 Nov;
23(1):46-57.e4.
PMID: 38007297
Background: ABP 215 is a biosimilar to the reference product, bevacizumab, and was one of the first biosimilars approved by Health Canada for the first-line treatment of metastatic colorectal cancer...
4.
Bessissow T, Narula N, Ma C, In T, Eberg M, Karra K, et al.
Dig Liver Dis
. 2023 Sep;
56(1):61-69.
PMID: 37716860
Background: Clinical practice guidelines recommend ustekinumab as a first-line biological treatment option for moderately-to-severely active Crohn's disease (CD). However, there is limited real-world effectiveness and safety data in bio-naïve patients....
5.
Anglin P, Elia-Pacitti J, Eberg M, Muratov S, Kukaswadia A, Sharma A, et al.
Curr Oncol
. 2023 Jun;
30(6):5529-5545.
PMID: 37366901
Background: With the emergence of therapies for mantle cell lymphoma (MCL), understanding the treatment patterns and burden of illness among older patients with MCL in Canada is essential to inform...
6.
Kuruvilla J, Ewara E, Elia-Pacitti J, Ng R, Eberg M, Kukaswadia A, et al.
Curr Oncol
. 2023 May;
30(5):4663-4676.
PMID: 37232810
Background: Many patients with advanced follicular lymphoma (FL) and marginal zone lymphoma (MZL) relapse after first-line chemotherapy. Objective: To examine healthcare resource utilization (HCRU) and cost, treatment patterns, progression, and...
7.
de Wet J, Ban J, Verdier G, Ling J, Eberg M, Bunko A, et al.
Int J Antimicrob Agents
. 2023 May;
62(2):106839.
PMID: 37160239
No abstract available.
8.
Milroy S, Wong J, Eberg M, Ieraci L, Forster K, Holloway C, et al.
Int J Qual Health Care
. 2023 Mar;
35(2).
PMID: 36961746
This study measures patient's concordance between clinical reference pathways with survival or cost among a population-based cohort of colon cancer patients applying a continuous measure of concordance. The primary hypothesis...
9.
Holloway C, Shabestari O, Eberg M, Forster K, Murray P, Green B, et al.
Curr Oncol
. 2022 Aug;
29(8):5338-5367.
PMID: 36005162
Breast cancer recurrence is an important outcome for patients and healthcare systems, but it is not routinely reported in cancer registries. We developed an algorithm to identify patients who experienced...
10.
Ieraci L, Eberg M, Forster K, Murray P, Borg E, Habbous S, et al.
Int J Cancer
. 2022 Feb;
150(12):2046-2057.
PMID: 35170750
Clinical cancer pathways help standardize healthcare delivery to optimize patient outcomes and health system costs. However, population-level measurement of concordance between standardized pathways and actual care received is lacking. Two...